Phosphodiesterase type 5 inhibitors for lower urinary tract symptoms induced by benign prostatic hyperplasia: an update / 中华男科学杂志
National Journal of Andrology
;
(12): 651-656, 2014.
Article
in Chinese
| WPRIM
| ID: wpr-309659
ABSTRACT
Medication has become the first-line option for the management of lower urinary tract symptoms induced by benign prostatic hyperplasia (LUTS/BPH) for its advantages in controlling the symptoms, inhibiting BPH progression, and reducing serious complications and surgical risks. Recent years have witnessed remarkable achievement in the studies of phosphodiesterase type 5 inhibitors (PDE5-Is) in the treatment of LUTS/BPH. PDE5-Is can effectively alleviate LUTS/BPH, with even better efficacy when combined with al-ARAs.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prostatic Hyperplasia
/
Therapeutic Uses
/
Drug Therapy
/
Phosphodiesterase 5 Inhibitors
/
Lower Urinary Tract Symptoms
Limits:
Humans
/
Male
Language:
Chinese
Journal:
National Journal of Andrology
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS